The JDP2 Knockout Jurkat Polyclonal Cells are a genetically modified human T lymphocyte cell population generated by CRISPR/Cas9-mediated disruption of the JDP2 gene. This product comprises a heterogeneous mixture of Jurkat cells carrying targeted disruptions at the JDP2 locus, providing a robust polyclonal knockout model that avoids clonal selection artifacts. The targeted gene disruption abolishes JDP2 protein expression, enabling functional studies of JDP2-dependent transcriptional regulation and its role in T cell signaling and leukemogenesis.
Jurkat cells are an immortalized human T lymphocyte leukemia cell line derived from the peripheral blood of an adolescent with acute T cell leukemia. This widely employed model recapitulates key aspects of T cell receptor (TCR) signaling, apoptosis, and HIV infection, making it particularly suitable for investigating the molecular mechanisms governing T cell activation and malignant transformation. The Jurkat background provides a physiologically relevant cellular context for dissecting JDP2 function in immune cell biology and leukemia.
JDP2 (Jun Dimerization Protein 2) is a basic leucine zipper transcription factor that acts as a potent repressor of AP-1 (Activator Protein 1) activity. It forms heterodimers with AP-1 components such as c-Jun, JunB, and JunD, and recruits histone deacetylase 3 (HDAC3) to promoter regions, leading to chromatin compaction and transcriptional silencing. JDP2 is phosphorylated and regulated by upstream MAPK cascades including ERK and JNK, and it interacts with cofactors like ATF2, p300/CBP, and p53. Downstream, JDP2 modulates the expression of genes critical for cell cycle progression (e.g., Cyclin D1), matrix remodeling (MMP-1, MMP-3), apoptosis (Bax, Bcl-2, p53), and cytokine signaling (IL-2). Disruption of JDP2 relieves this repression, thereby enhancing AP-1-driven transcription and altering cellular responses to mitogenic and stress signals.
In the Jurkat T lymphocyte model, JDP2 knockout profoundly influences the AP-1 transcription factor network, which is central to TCR-mediated activation, proliferation, and programmed cell death. Loss of JDP2-mediated repression leads to deregulated expression of AP-1 target genes, impacting cell cycle progression and apoptosis sensitivity. This knockout system is thus a powerful tool for dissecting the role of JDP2 in leukemia biology, where AP-1 dysregulation is frequently implicated, and for exploring how JDP2 interacts with oncogenic signaling pathways in T cell malignancies.
This polyclonal knockout cell population is ideally suited for a wide range of experimental applications, including quantitative gene expression analysis by RT-qPCR and RNA-seq, protein detection via Western blotting, and genome-wide chromatin immunoprecipitation (ChIP) to map JDP2-dependent epigenetic changes. Functional assays such as flow cytometry for apoptosis and cell cycle analysis, luciferase reporter assays to measure AP-1 transcriptional activity, and co-immunoprecipitation for protein interactome studies are readily performed. Additionally, these cells provide a valuable platform for drug sensitivity screening and investigation of JDP2-dependent therapeutic responses. For further technical inquiries or additional product information, please contact Ascent Research.
